EGFR and lung adenocarcinoma: The use of tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in EGFR-mutant lung adenocarcinoma patients successfully causes tumor regression and prolonged patient survival; [6] however, drug resistance and tumor relapse eventually occur.